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ABSTRACT 
As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care 
Excellence (NICE) invited the manufacturer of adalimumab (AbbVie) to submit evidence on the 
clinical effectiveness and cost-effectiveness of adalimumab for the treatment of moderate-to-severe 
hidradenitis suppurativa (HS). The appraisal assessed adalimumab as monotherapy in adult patients 
with an inadequate response to conventional systemic HS therapy. The School of Health and Related 
Research Technology Appraisal Group was commissioned to act as the independent Evidence Review 
Group (ERG). The ERG produced a critical review of the evidence for the clinical effectiveness and 
cost-HIIHFWLYHQHVVRIWKHWHFKQRORJ\EDVHGRQWKHFRPSDQ\¶VVXEPLVVLRQWR1,&(7KHevidence was 
mainly derived from three randomised controlled trials comparing adalimumab with placebo in adults 
with moderate-to-severe HS. The clinical effectiveness review found that significantly more patients 
achieved a clinical response in the adalimumab groups than the control groups, but that the treatment 
effect varied between trials and there was uncertainty regarding its impact on a range of other relevant 
outcomes, as well as long-term efficacy. 7KH FRPSDQ\¶V submitted Markov model assessed the 
incremental cost-effectiveness of adalimumab versus standard care for the treatment of HS from the 
perspective of the National Health Service (NHS) and Personal Social Services (PSS) over a lifetime 
horizon. The original submitted model, which included a Patient Access Scheme (PAS), suggested 
that the incremental cost-effectiveness ratio (ICER) for adalimumab versus standard care is expected 
to be £16,162 SHU4$/<JDLQHG)ROORZLQJDFULWLTXHRIWKHPRGHOWKH(5*¶VSUHIHUUHGEDVHFDVH
which corrected programming errors and structural problems surrounding discontinuation rules, and 
incorporated a lower unit cost for HS surgery, resulted in a probabilistic ICER of £29,725 per QALY 
gained. Based on additional analyses undertaken by the company and the ERG following the 
publication of the Appraisal Consultation Document (ACD), the appraisal committee concluded that 
the maximum possible ICER for adalimumab compared with supportive care was between £28,500 
and £33,200 per QALY gained, but was likely to be lower. The appraisal committee recommended 
adalimumab (with the PAS) for the treatment of active moderate-to-severe HS in adults whose disease 
has not responded to conventional systemic therapy. 
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KEY POINTS FOR DECISION-MAKERS 
x Based on evidence provided from 3 RCTs and one OLE study, the Appraisal Committee 
agreed that adalimumab is efficacious and safe in producing a clinical response in adults with 
moderate-to-severe hidradenitis suppurativa (HS) with an inadequate response to 
conventional systemic therapy. 
x There was uncertainty regarding the long-term effectiveness and safety of adalimumab, the 
costs associated with HS surgery and the extent to which adalimumab might reduce these 
costs, DQG WKH GHILQLWLRQV RI ³SDUWLDO UHVSRQVH´ DQG ³QR UHVSRQVH´ based on the HiSCR 
measure. 
x %DVHG RQ WKH (5*¶V H[SORUDWRU\ DQDO\VHV WKH FRPPLWWHH FRQFOXGHG WKDW WKH PD[LPXP
possible ICER for adalimumab, compared with supportive care, was between £28,500 and 
£33,200 per QALY gained, but was likely to be lower. 
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1. INTRODUCTION 
Health technologies must be shown to represent a clinically effective and cost-effective use of 
resources in order to be recommended for use within the NHS in England. The National Institute for 
Health and Care Excellence (NICE) is an independent organisation responsible for providing national 
guidance on promoting good health and preventing and treating ill health in priority areas with a 
significant impact. The NICE Single Technology Appraisal (STA) process usually covers new 
technologies within a single indication, shortly after they have received UK marketing authorisation 
[1]. Within this process, the company provides NICE with a written submission that summarises the 
FRPSDQ\¶V HVWLPDWHVRI WKH FOLQLFDO HIIHFWLYHQHVVDQGFRVW-effectiveness of the technology, together 
with an executable health economic model. 7KH FRPSDQ\¶V VXEPLVVLRQ &6 is reviewed by an 
external organisation independent of NICE, the Evidence Review Group (ERG), which consults with 
clinical specialists and produces an ERG report. After consideration of the CS, the ERG report and 
testimony from experts and other stakeholders, the NICE Appraisal Committee formulates 
preliminary guidance in the form of an Appraisal Consultation Document (ACD) which indicates the 
&RPPLWWHH¶V LQLWLDO UHFRPPHQGDWLRQV RQ WKH XVH RI WKH Wechnology. Stakeholders are subsequently 
invited to comment on the submitted evidence and the ACD, after which a subsequent ACD may be 
produced or a Final Appraisal Determination (FAD) is issued, which is open to appeal. An ACD is not 
produced when the technology is recommended without restriction; in such instances, the FAD is 
produced directly. This paper presents a summary of the ERG report [2] and subsequent analyses [3, 
4] for the STA of adalimumab for the treatment of active moderate-to-severe hidradenitis suppurativa, 
and the subsequent development of the NICE guidance for the use of this drug in England [5]. Full 
details of all relevant appraisal documents can be found on the NICE website 
(https://www.nice.org.uk/guidance/ta392).  
 
2. THE DECISION PROBLEM 
Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic, inflammatory, recurrent, 
debilitating, skin follicular disease that usually presents after puberty with painful deep-seated, 
inflamed lesions. In patients with HS, hair follicles in the apocrine gland-bearing regions (axilla, 
genital area, groin, infra-mammary region, peri-anal region and buttocks) become blocked and 
inflamed, resulting in painful recurrent deep-seated boils and nodules. Boils and nodules may progress 
to abscesses, sinus tracts and scarring. In most patients, disease flares occur at varying intervals, often 
pre-menstrually in women. Disease flares are characterised by increased pain and suppuration with a 
foul smelling discharge which stains clothing. HS affects young adults, with disease onset typically 
between the second and fourth decades of life [6, 7]. Within the adult European population, a 
prevalence of 1% has been reported [8], although true prevalence is likely to be higher due to 
problems of under-recognition [9, 10]. Whilst there are no published data on HS prevalence in the 
UK, it has been suggested that this might be in the region of 1 in 600 [6]. HS has a higher prevalence 
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in women than men and around one-third of patients have the disease in first-degree relatives. The 
other important known risk factors for HS are obesity and cigarette smoking [8-10]. Studies have 
suggested that active disease can substantially impair patients¶ health-related quality of life (HRQoL), 
with an impact which exceeds that of other skin diseases such as alopecia, acne, mild to moderate 
psoriasis, vascular anomalies of the face and atopic dermatitis. Given the debilitating impact of HS, 
measures of pain and HRQoL, especially the Dermatology Quality of Life Index (DLQI), are 
recognised as being useful for clinical management of the disease [8, 10]. 
 
2.1 Current treatment 
There is no current standard of care for HS in England. Treatment is usually determined by the 
specifics of the disease in the individual patient, together with clinical and patient experience. 
Treatment usually aims to control the disease and to reduce the number of outbreaks; total cure is 
generally not expected. Alongside lifestyle changes (smoking cessation and weight loss), therapeutic 
options include topical antiseptics and antibiotics, systemic antibiotics (e.g. oral tetracyclines, 
clindamycin and rifampicin), anti-androgens, systemic retinoids, immunomodulatory agents, laser 
treatment, surgery and tumour necrosis factor-alpha (TNF-Į LQKLELWRUV [11-13]. Treatment choices 
typically depend on the frequency, severity and spread of lesions and also gender in the case of the 
retinoid acitretin. A survey of current practice among UK dermatologists confirmed that, after topical 
treatments, oral antibiotics, such as lymecycline or doxycycline, represent the first-line medical 
treatment of choice, followed by clindamycin and rifampicin, dapsone, acitretin, ciclosporin, 
depending on response and gender [13]. In addition, TNF-Įinhibitors, such as etanercept, infliximab 
and adalimumab are already being used for the treatment of moderate-to-severe HS in England. 
Surgery is usually an option after medical treatments have failed and might involve simple local 
incision and drainage (usually as a response to acute flares, rather than to control the disease or reduce 
recurrence); narrow margin excision (which might see recurrence at the edge of the excised area), 
and; wide margin excision for patients with advanced disease.  
 
In October 2015, NICE issued a final scope to appraise the clinical effectiveness and cost-
effectiveness of adalimumab for active moderate-to-severe HS in adult patients with an inadequate 
response to conventional systemic HS therapy [14]. 
 
3. INDEPENDENT ERG REVIEW 
The company (AbbVie) provided a submission to NICE on the clinical effectiveness and cost-
effectiveness of adalimumab for the treatment of moderate-to-severe HS [15]. This submission was 
critically appraised by the ERG. In addition, the ERG identified areas requiring clarification, for 
which the company provided additional evidence prior to completion of the ERG report [16].  
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3.1.1 Clinical evidence submitted by the company 
The clinical evidence consisted of three separate reviews: (1) a review of clinical efficacy evidence 
from RCTs of treatments for HS, specifically trials comparing adalimumab with placebo in adults 
with moderate-to-severe HS: a PhDVH ,, ³GRVLQJ´ WULDO 0-467 [17], and two Phase III trials, 
PIONEER I and II [18, 19]; (2) a review of evidence from a non-controlled open-label extension 
(OLE) study (M12-555) [20], and; (3) a review of safety evidence from the RCTs and the OLE study. 
The relevant efficacy data were derived from Period 1 of the M10-467 trial (up to week 16) and 
Periods A and B in the PIONEER trials, i.e. weeks 0-12 and weeks 12-36, respectively. The initial 
periods in all trials compared adalimumab 40mg every week (EW) with placebo. The second period in 
the PIONEER trials was initiated by re-randomisation of patients at week 12 to adalimumab 40mg 
EW, placebo or adalimumab 40mg every other week (EOW). The three RCTs and the OLE study 
were all reported by the company to be at low risk of bias following quality assessment using a range 
of critical appraisal tools [15].  
 
In M10-467, significantly more patients in the adalimumab 40mg EW group achieved a clinical 
response (defined as achieving a +LGUDGHQLWLV6XSSXUDWLYD3K\VLFLDQ¶VGlobal Assessment [HS-PGA] 
score of clear, minimal or mild with at least a 2 grade improvement relative to baseline at week 16) 
than patients receiving placebo: 17.6% versus 3.9% (p<0.025). Significant improvements were also 
observed at week 16 in individual symptoms, overall disease severity and pain scores for adalimumab 
40mg EW compared with placebo. In the PIONEER trials, clinical response was evaluated by 
Hidradenitis Suppurativa Clinical Response (HiSCR), defined as 50% reduction in the total abscess 
and inflammatory nodule [AN] count with no increase in abscess count or draining fistula count [17]. 
In Period A of PIONEER I and II (at week 12), significantly more patients in the adalimumab 40mg 
EW group achieved clinical response relative to baseline compared with patients receiving placebo 
(PIONEER I ± adalimumab 41.8%, placebo 26.0%, p=0.003; PIONEER II ± adalimumab 58.9%, 
placebo 27.6%, p<0.001). Significant improvements were observed in symptoms, disease severity 
(according to the Modified Sartorius Severity [MSS] score) and pain in PIONEER II. However, in 
PIONEER I, some of the improvements with adalimumab 40mg EW were numerically but not 
significantly better than placebo. Subgroup analyses indicated that patients achieved benefit with 
adalimumab 40mg EW regardless of their baseline characteristics, although analyses were subject to 
small patient numbers. In PIONEER I and II, adalimumab 40mg EW significantly improved HRQoL 
as measured by the EQ-5D, the DLQI, and the physical components of the Short-Form 36 (SF-36) 
compared with placebo; improvements were not significant across all components of SF-36. The 
treatment effect therefore varied between the trials. The CS did not include a pairwise meta-analysis 
of the PIONEER trials and a network meta-analysis (NMA) was not considered feasible. 
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Some improvements were maintained into the second period of the PIONEER trials up to 36 weeks 
(Period B). During Period B, there was also a loss of effect for patients re-randomised to placebo or 
adalimumab 40mg EOW. The company stated that re-randomisation at week 12 and protocol-driven 
discontinuation during Period B for patients with Loss of Response (LOR) or Worsening or Absence 
of Improvement (WOAI), led to low patient numbers in the group receiving adalimumab 40mg EW 
for the total study duration, meaning the analyses were underpowered.  
 
These trials were supplemented by one unpublished, non-randomised, non-controlled, unblinded OLE 
study of the PIONEER trials (M12-555). The CS included an interim analysis of efficacy from this 
study, however patient numbers were small. Results for secondary efficacy outcomes were not 
reported. 
 
The review of safety evidence included the three RCTs and the OLE study. Adalimumab 40mg EW 
was well-tolerated in all three RCTs. The proportion of patients experiencing serious adverse events 
(SAEs) or discontinuing treatment due to AEs was low and was similar in both the adalimumab and 
placebo arms. In an integrated summary of PIONEER I and II (n=633), six patients receiving placebo 
(1.9%) and three receiving adalimumab 40mg EW (0.9%) gave AEs as their primary reason for 
discontinuation during Period A. The most common AEs were exacerbation of HS, nasopharyngitis 
and headache. Rates of infectious AEs were similar for patients receiving adalimumab and for those 
receiving placebo. M12-555 is the only ongoing study of adalimumab for HS; final data were not 
available at the time of the appraisal. 
 
3.1.2 Critique of clinical effectiveness evidence and interpretation 
The principal efficacy review was a poorly-reported systematic review of 3 relevant RCTs. The 
PIONEER trials were published only as abstracts, so clinical study reports (CSRs) provided by the 
company were the principal source of data and were used for quality assessment purposes. The 
primary outcome was clinical response, measured in the PIONEER trials using the HiSCR measure 
developed by the company. Clinical advice received by the ERG confirmed that HiSCR had been 
validated but, in terms of clinical decision-making, its findings should be viewed alongside patient-
reported outcome measures (PROMs), in particular the DLQI and a pain measure [17, 21]. The ERG 
agreed with the company that the M10-467 trial was at low risk of bias for the relevant Period 1 (up to 
week 16). The ERG also conducted a critical appraisal of the RCTs using the Cochrane Risk of Bias 
tool [22] and the OLE study using the Critical Appraisal Skills Programme (CASP) cohort study tool 
[23]. The ERG considered the results from Period A (up to week 12) in PIONEER I and II to be 
generally at low risk of bias. However, the ERG considered there to be a moderate or unclear risk of 
selection, attrition and reporting bias affecting the results of Period B in the PIONEER trials, given 
the absence of any evaluation of blinding, the high levels of attrition, the imputation methods used to 
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manage some of the missing data, and some differences between the outcomes reported in the 
protocol and those reported in the publications and CSRs. 
 
The ERG accepted that the percentage of patients achieving clinical response according to the HiSCR 
measure on adalimumab 40mg EW at week 12 or week 16 was significantly higher than in the 
placebo groups (p<0.01), but noted that the treatment effect varied between the trials. Significant or 
clinically relevant differences in favour of adalimumab 40mg EW that were reported for secondary 
outcomes in PIONEER II were not always found for those outcomes in PIONEER I, especially for 
AN count, MSS score, pain and some components of the SF-36. The reasons for these between-trial 
differences were unclear.  
 
The company conducted an arm-based integrated summary, which breaks randomisation, for the 
3,21((5WULDOVWRWDEXODWH3HULRG%UHVSRQVHIRUDOOSDWLHQWVDQGIRUDJURXSRI+L6&5³UHVSRQGHUV´
DQG³SDUWLDO UHVSRQGHUV´7KLV³SDUWLDOUHVSRQGHU´JURXSGHILQHGDV+L6&5UHVSRQGHUV ZLWK
AN UHGXFWLRQUDWKHUWKDQUHGXFWLRQwas not a pre-specified response category in the PIONEER 
trials, nor was it explained or justified in the CS, and its clinical validity had not been demonstrated. 
The ERG considered that findings based on this post hoc ³SDUWLDO UHVSRQGHU´JURXSZHUH WKHUHIRUH
uncertain. A small number of secondary outcomes were reported for Period B in PIONEER I and II, 
but only for patients who had had a clinical response at week 12, and the sample sizes in this later 
period were small. 
 
The ERG considered the efficacy results from the OLE study to be uncertain because they were drawn 
from interim analyses of unpublished study data. This study also only offered efficacy data for up to 
72 weeks for a drug that might be taken for many years by patients with moderate-to-severe HS. 
There were no obvious safety concerns, with most AEs being balanced between groups, and small 
numbers of SAEs were reported. The ERG considered that longer-term data were required to 
determine whether reported AE rates could be maintained for patients on long-term adalimumab 
maintenance treatment; whether certain subgroups of patients were at a higher risk of certain events, 
and; to confirm whether there were any differences between interrupted and uninterrupted regimens. 
 
3.2 Cost-effectiveness evidence submitted by the company 
The company submitted a de novo Markov model to assess the cost-effectiveness of adalimumab 
versus standard care for moderate-to-VHYHUH +6 7KH FRPSDQ\¶V PRGHO estimates costs and health 
outcomes from the perspective of the National Health Service (NHS) and Personal Social Services 
(PSS) over a lifetime horizon (66 years). Health outcomes and costs were discounted at a rate of 3.5% 
per annum. Costs were valued at 2013/14 prices. All analyses relate to the full licensed population for 
adalimumab; no subgroup analyses were presented. Following the submission of the original ERG 
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report, a Patient Access Scheme (PAS) in the form of a confidential price discount was agreed for 
adalimumab specifically in the HS indication. 
 
7KH FRPSDQ\¶V PRGHO LQFOXGHV ILYH PXWXDOO\ H[FOXVLYH KHDOWK VWDWHV EDVHG RQ GHSWK RI +L6&5
response: (i) high response; (ii) response; (iii) partial response; (iv) no response, and; (v) dead (see 
Table 1). Patients are allowed to transit between any of the living health states during each cycle. The 
model uses a 2-week cycle length for the first 2 cycles, and a 4-week cycle length thereafter. Health 
state transitions were modelled up to week 36 using pooled data from the PIONEER I/II trials, 
including a discontinuation rule for patients receiving adalimumab who do not achieve at least a 
partial response by week 12 (see Table 2). The long-term HiSCR trajectory of adalimumab responders 
(including partial responders) beyond 36 weeks was subsequently modelled using a time-invariant 
generalised logit model (GLM) fitted to last observation carried forward (LOCF)-imputed data from 
the OLE study. The long-term HiSCR trajectories for patients receiving standard care and for those 
who have previously discontinued adalimumab beyond 36 weeks were modelled using separate time-
invariant GLMs fitted to data from weeks 12-36 from the PIONEER I/II trials. The CS stated that the 
model assumes that patients who lose response after week 36 will continue to receive adalimumab for 
a further 12 weeks, although this did not accurately reflect WKH PRGHO¶V LPSOHPHQWDWLRQ. Health 
utilities were based on depth of HiSCR response using a post hoc analysis of EQ-5D data collected 
within PIONEER II. Resource use was differentiated by depth of HiSCR response based on a survey 
of UK physicians undertaken by the company and included: inpatient visits due to HS surgery; 
outpatient visits due to HS surgery; wound care visits due to HS surgery; non-surgical inpatient visits; 
non-surgical outpatient visits; wound care visits not due to HS surgery; Accident and Emergency 
(A&E) visits, and; costs associated with AEs. Unit costs were taken from the British National 
Formulary [24], the Personal Social Services Research Unit [25] and NHS Reference Costs [26]. AEs 
were assumed to impact only on costs. 
 
Table 1: HiSCR response categories 
[INSERT TABLE 1 HERE] 
 
Table 2: Evidence used to inform the model transition matrices 
[INSERT TABLE 2 HERE] 
 
The probabilistic version RI WKHFRPSDQ\¶VPRGHO (including the PAS) suggests that adalimumab is 
expected to produce an additional 1.02 QALYs at an additional cost of £16,471 compared with 
standard care; the incremental cost-effectiveness ratio (ICER) for adalimumab versus standard care is 
expected to be £16,162 per QALY gained. The deterministic results were similar (ICER=£15,182 per 
QALY gained). Assuming willingness-to-pay thresholds of £20,000 and £30,000 per QALY gained, 
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WKHFRPSDQ\¶VPRGHOVXJJHVWVWKDW WKHSUREDELOLW\ WKDWDGalimumab produces more net benefit than 
standard care is approximately 0.58 and 0.80, respectively. The ICER for adalimumab was greater 
than £30,000 per QALY gained in four scenario analyses: (i) time horizon=20 years; (ii) use of 
PIONEER II data only; (iii) use of last state carried forward imputation, and; (iv) discontinuation rate 
for adalimumab non-responders after week 36 based on the OLE study.  
 
3.2.1 Critique of cost-effectiveness evidence and interpretation 
7KH (5* FULWLFDOO\ DSSUDLVHG WKH FRPSDQ\¶V HFRQRPLF DQDO\VLV DQG GRXEOH-programmed the 
FRPSDQ\¶VPRGHOThe main issues identified by the ERG are discussed below; the full critique can be 
found in the ERG report and subsequent addenda [2-4]. 
3.2.1.1 Appropriateness of modelling according to depth of HiSCR response 
7KH FRPSDQ\¶V PRGHO VWUXFWXUH divides the HiSCR measure into four response categories. The CS 
justified this disaggregation based on a post hoc analysis which suggested statistically significant 
differences in EQ-5D between the high response and response states, and between the partial response 
and non-response states in PIONEER II. The ERG noted the following concerns: 
(i) Disaggregating the full HiSCR measure according to depth of response represents a post hoc 
analysis of a pre-planned endpoint. 
(ii) The HiSCR validation study reported by Kimball et al relates specifically to the full HiSCR 
WKUHVKROG  UHGXFWLRQ LQ $1V ZLWK QR LQFUHDVH LQ DEVFHVVHV or draining fistulas from 
baseline) [17]. Kimball et al reported that patients with worsening disease or minimal 
improvement in ANs (<30% reduction) did not have a meaningful improvement on the DLQI 
and reported some worsening in pain despite improvements in total work impairment and 
total activity impairment. Kimball also reported no substantial incremental benefits on patient 
UHSRUWHGRXWFRPHVEH\RQGWKH$1UHGXFWLRQWKUHVKROG 
(iii) EIILFDF\GDWDIURPWKH3,21((5,,,WULDOVDUH³VWUHWFKHG´DFUoss four rather than two states, 
hence, several cells in the transition matrices are populated with small patient numbers.  
 
Based on the health state definitions and treatment continuation rules, WKHFRPSDQ\¶VPRGHOimplicitly 
suggests that the 50% AN reduction threshold determined in the Kimball validation study, and later 
pre-specified as the primary endpoint in the PIONEER trials, has been set at the wrong level for 
clinical practice. 
 
3.2.1.2 Disconnect between evidence used to inform efficacy and costs 
TKHFRPSDQ\¶VPRGHOOHGKHDOWKJDLQVDQGWKHUHVRXUFHVUHTXLUHG to generate those health gains were 
derived from different sources: health outcomes were modelled using observed trial data or GLMs 
fitted to HiSCR outcomes from the PIONEER trials, whilst resource use was based on surgery-related 
and non-surgery-related secondary care resource estimates from a survey of UK physicians [15]. 
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Higher resource use was assumed for patients achieving a weaker response or no response, hence 
improvements in modelled HiSCR state are assumed to lead to reductions in costs. The ERG had 
concerns regarding whether the FRPSDQ\¶V PRGHOOHG SUHGLFWLRQV of overall resource use reflect the 
experience of patients enrolled into the PIONEER I/II trials. Whilst the CS asserted that adalimumab 
may delay or reduce the need for surgery, and this was reflected in the model, this potential treatment 
benefit had not been substantiated by evidence. As part of the clarification process, the company 
presented a post hoc analysis of the PIONEER I/II studies which showed that that at week 12, more 
patients who received adalimumab, compared with placebo, experienced elimination of both draining 
fistulas (33% vs 19%; p<0.001) and non-draining fistulas (15% vs 9%; p=0.017). These data do not 
however directly reflect overall reductions in surgery, particularly inpatient surgical admissions, 
which are a key cost driver in the model. Further, WKH (5*¶V DGYLVRUV noted that whilst the 
adalimumab could reduce the extent to which limited surgical procedures are required for patients 
with previously uncontrolled disease, it may in some instances EHXVHGDVDSUHDGMXYDQW³EULGJH´WR
more definitive surgery, thereby increasing surgery use.  
 
In addition, the costs of pharmacological therapies were not included in the model. Clinical advisors 
to the ERG were satisfied that the types of resource use included were generally relevant, but noted 
that some treatments (e.g. wound dressings, where needed) may be given in a primary care setting and 
that some patients will be prescribed antibiotics by their GPs for several years, yet these costs were 
not considered. Following clarification, the company provided estimates of concomitant medications 
used in >5% patients in Period A of the PIONEER I/II trials. These data suggested that concomitant 
pharmacological therapy use was broadly similar between the adalimumab and placebo groups, 
however this information relates only to the first 12 weeks of treatment within the RCTs and it 
remains unclear whether the inclusion of concomitant medication costs would substantially impact 
upon the cost-effectiveness of adalimumab over a lifetime horizon.  
 
3.2.1.3 Treatment continuation rules 
The model assumes that patients require only a partial HiSCR response in order to continue treatment. 
The ERG¶VDGYLVRUV were unclear whether patients achieving a partial HiSCR response (which could 
include increases in abscesses and/or draining fistulae) would obtain a clinically meaningful benefit 
sufficient to warrant continuing adalimumab treatment. Commentators on the validity of the HiSCR 
measure have highlighted the need to capture other aspects of treatment benefit such as pain and 
improvements on the DLQI [21].  
 
,Q DGGLWLRQ WKH FRPSDQ\¶V PRGHO LQFOXGHV DQ DVVXPSWLRQ ZKHUHE\ SDWLHQWV UHFHLYLQJ DGDOLPXPDE
who continue to achieve no response from treatment receive an additional 12 weeks of adalimumab 
before discontinuing. This was applied in the model by raising the probability of remaining in the 
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adalimumab no response state for one cycle (from the OLE GLM) to the power of 3 and adjusting all 
other transitions in the row accordingly. This matrix was applied from week 48 onwards. This 
assumption led to patients discontinuing adalimumab more quickly, thereby substantially reducing the 
total adalimumab treatment costs. The ERG noted that this approach was mathematically incorrect as 
the cubed probability reflects the 12-week probability of remaining in the no response state for three 
4-week cycles. The proposed discontinuation rule should have been implemented using tunnel states. 
 
3.2.1.4 Potential overestimation of costs of surgery 
The ERG considered WKDW WKH FRPSDQ\¶V PRGHO RYHUHVWLPDWHG WKH OLIHWLPH FRVW RI VXUJHU\ LQ ERWK
groups, and that cost savings associated with adalimumab due to surgical procedures avoided, may 
not be realistic. Annual surgical inpatient admission rates according to HiSCR response state were 
EDVHGRQWKHFRPSDQ\¶Vphysician survey, whilst the unit cost was derived from NHS Reference Costs 
2013/14 (major skin procedures, elective inpatient, length of stay [LOS] = 5.1 days) [26]. The 
FRPSDQ\¶V PRGHO predicted that the average patient receiving standard care will require 33.87 
inpatient surgical admissions over their remaining lifetime, whilst patients receiving adalimumab 
would require 29.78 admissions. The ERG noted that the tariff cost of £5,488.32 and its associated 
LOS was likely to broadly reflect a wide excision procedure. Clinical advisors to the ERG suggested 
that excluding the management of surgical complications, the maximum number of sites which may 
require wide excision for a patient with very extensive disease would be 6-10 (including breasts, 
groin, the perineum, armpits and buttocks). Patients with less extensive disease would require fewer 
wide excisions than this maximum number and in some cases more than one region can be treated in 
WKH VDPH VXUJLFDO HSLVRGH7KH(5*¶VFOLQLFDO DGYLVRUVDOVR VXJJHVWHG WKDWSDWLHQWs may undergo a 
comparatively higher number of smaller less costly procedures such as incision and drainage and 
narrow margin excision.  
 
3.2.1.5 Other issues identified by the ERG 
Several further issues were identified by the ERG, although these had a less significant impact upon 
the ICER for adalimumab. These included: (i) the use of pooled arm-based summaries of trial data 
rather than a formal NMA; (ii) minor programming errors; (iii) inconsistent handling of time-
dependence in transition probabilities for different time periods, and; (iv) potential bias associated 
with using the OLE data for adalimumab responders. 
 
3.3 Additional work undertaken by the ERG 
The ERG undertook exploratory analyses to resolve the identified programming errors and to explore 
alternative assumptions ZLWKLQWKHFRPSDQ\¶VPRGHO7KH(5*¶VSUHIHUUHGEDVHFDVHLQYROYHG(a) the 
correction of minor technical programming errors; (b) applying structural amendments to correctly 
UHIOHFWWKHFRPSDQ\¶VLQtended adalimumab non-responder continuation rule during the maintenance 
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phase, and; (c) re-estimation of surgery costs. The (5*¶VVXUJHU\FRVt estimates assumed that patients 
on average undergo 2 wide excisions over their lifetime, with the remaining procedures being 
intermediate day case procedures without admission or elective/non-elective intermediate skin 
procedures with an LOS of 2 days; this resulted in an estimated cost per procedure of £1,525.74. 
Further analyses were undertaken to explore uncertainty surrounding transition probabilities, the 
likely impact of altering induction phase discontinuation rules and some exploration of uncertainty 
around the model structure.  
 
The exploratory analyses indicated that the programming errors did not materially alter the ICER for 
adalimumab. The incorporation of tunnel states for adalimumab non-responders within the 
maintenance phase of the corrected model increased the ICER for adalimumab versus standard care 
(ICER=£19,551 SHU 4$/< JDLQHG 7KH (5*¶V preferred base case, which comprises a scenario 
whereby these two sets of corrections are combined with the lower surgery cost, resulted in a 
probabilistic ICER of £29,725 per QALY gained.  
 
3.4 Conclusion of the ERG report 
The ERG considered the RCT evidence to be robust for the initial trial periods up to 12 or 16 weeks. 
However, the treatment effect varied between studies; the reasons for this were unclear. Efficacy 
results from Period B of the PIONEER trials were at a higher risk of bias across some domains, and 
ZHUH DIIHFWHG E\ WKH PHUJLQJ RI ³UHVSRQGHUV´ ZLWK ³SDUWLDO UHVSRQGHUV.´ 7KH VDIHW\ HYLGHQFH ZDV
generally at low risk of bias but was limited, and several questions remain around AE rates for 
SDWLHQWV RQ ³FRQWLQXRXV´ RU ORQJ-term adalimumab 40mg EW. The (5*¶V exploratory analyses 
suggested that the probabilistic ICER for adalimumab versus standard care is £29,725 per QALY 
gained. 
 
4. METHODOLOGICAL ISSUES 
The principal areas of uncertainty in the clinical evidence relate to potential treatment effect modifiers 
and short study follow-up. These uncertainties exist due to observed differences in certain outcomes 
or levels of outcome between trials, differences in disease severity and other baseline characteristics 
between trials, and the amount of missing data and imputed results beyond 12 weeks in the PIONEER 
trials and the OLE study. The ERG also noted issues with respect to whether the achievement of a 
³SDUWLDO UHVSRQVH´ DFFRUGLQJ WR WKH +L6&5 PHDVXUH UHSUHVHQWV D FOLQLFDOly meaningful treatment 
benefit sufficient to warrant continuing adalimumab.  
 
7KH FRPSDQ\¶V PRGHO was subject to several methodological issues. In particular, the ERG had 
concerns that the use of a 5-state model which included three responder categories may have 
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³stretched´ the available data too far and that a 3-state model (including response, no response and 
dead) may have represented a better use of the available evidence. The ERG also noted a selection 
bias in that patients who discontinued adalimumab after losing a prior response to therapy were 
assumed to have a different trajectory through the model (indefinitely) compared with patients 
receiving standard therapy alone. The joint impact of these issues on the ICER for adalimumab was 
unclear. 
5. NICE GUIDANCE 
The appraisal committee reviewed the data available on the clinical effectiveness and cost-
effectiveness of adalimumab, having considered evidence on the nature of HS and the value placed on 
the benefits of adalimumab by people with the condition, those who represent them, and clinical 
experts. It also took into account the effective use of NHS resources.  
 
The ACD (published February 2016) states that the committee was minded not to recommend 
adalimumab for the treatment of active moderate-to-severe HS. The ACD requested additional 
analyses including: a formal meta-analysis of the PIONEER I/II trials; WKH FRPPLWWHH¶V SUHIHUUHG
assumption about treatment discontinuation for non-responders at 36 weeks or later, a re-analysis of 
the PIONEER I/II data used in the model in which partial response is defined as a 25% to 50% 
reduction in AN count and no increase in abscesses and draining fistulas, and an analysis in which 
extrapolation of outcomes for adalimumab responders was based on the PIONEER I/II trials rather 
than the OLE study. The ACD also requested additional information from the company relating to 
resource use estimates derived from the physician survey, utility values within PIONEER II, methods 
IRUGHULYLQJWUDQVLWLRQPDWULFHVIURPWKH2/(VWXG\DQGFODULW\UHJDUGLQJWKHFRPSDQ\¶VDWWHPSWVWR
validate model predictions against the observed PIONEER I/II data. 
 
Subsequently, the company submitted the requested analyses and additional information. The 
FRPSDQ\¶V$&'UHVSRQVHDOVRLQFOXGHGDUHYLVHGPRGHOZKLFKincorporated the results of NMAs, the 
correction of programming errors, WKH FRPPLWWHH¶V SUHIHUUHG DVVXPSWLRQ UHJDUGLQJ WUHDWPHQW
discontinuation in non-responders beyond 36 weeks and some structural changes. The revised model 
retained the original surgery cost of £5,488.32 per episode.  
 
The ERG was broadly satisfied that the NMA had been undertaken appropriately. However, within 
the revised model, the NMA-derived transition matrices had been erroneously inverted (transitions to 
states 1, 2, 3, and 4 were inputted as transitions to states 4, 3, 2, and 1). In addition, the ERG 
identified a further error whereby the incorrect discontinuation rate was applied during weeks 12-36. 
Rectifying these errors reduced the ICER to £10,770 per QALY gained. The ERG raised concerns 
regarding an unwritten assumption whereby different transition matrices were applied to adalimumab 
discontinuers compared with the standard care group: this led to a situation whereby patients 
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discontinuing adalimumab had a more favourable long-term prognosis compared with those who had 
never received adalimumab (e.g. a patient who discontinued adalimumab at 36 weeks would still be 
deriving benefit from therapy 20 years later). The ERG did not consider this to be clinically plausible 
and noted that removing this assumption increased the ICER for adalimumab. The ERG had further 
FRQFHUQV WKDW WKH FRPSDQ\¶V DGGLWLRQDO DQDO\VHV GLG QRW LQFOXGH WKH FRPPLWWHH¶V SUHIHUUHG
assumptions regarding surgery. The ERG also QRWHGWKDWWKHFRPSDQ\¶VDQDO\VHVZKLFKLQFOXGHGWKH
new definition of partial response had been applied only to the transition probabilities, but should also 
have impacted on health state costs, discontinuation rates and utilities. The ERG undertook further 
exploratory analyses ZKLFK LQFOXGHG WKH FRPSDQ\¶V 10$ WKH FRUUHFWHG GLVFRQWLQXDWion rate and 
alternative assumptions regarding the mean lifetime number of wide excisions. %DVHGRQWKH(5*¶V
exploratory analyses of this revised model, the committee concluded that the maximum possible 
ICER for adalimumab compared with supportive care was between £28,500 and £33,200 per QALY 
gained [27]. In May 2016, NICE published its FAD which makes the following recommendations:  
 
³1.1 Adalimumab is recommended, within its marketing authorisation, as an option for treating active 
moderate to severe hidradenitis suppurativa in adults whose disease has not responded to 
conventional systemic therapy. The drug is recommended only if the company provides it at the price 
agreed in the PAS.  
 
1.2 Assess the response to adalimumab after 12 weeks of treatment, and only continue if there is clear 
evidence of response, defined as:  
x a reduction of 25% or more in the total AN count and  
x no increase in abscesses and draining fistulas.´ 
 
5.1 Consideration of clinical and cost-effectiveness issues 
This section discusses the key issues considered by the appraisal committee. The full list can be found 
in the FAD [27]. 
 
5.1.1 Appropriate HiSCR threshold for determining treatment response and continuation 
The committee considered how clinicians assess disease severity and response to treatment in people 
with HS. The clinical experts considered that the HiSCR is a reliable and reproducible tool, which has 
been validated and is relevant to clinical practice, but noted that the minimum clinically important 
difference (MCID) has not been established. Clinical experts were aware that according to the HiSCR 
validation study, response was defined as a 50% reduction in total AN count, with no increase in 
abscesses or draining fistulas from baseline. However, clinical experts considered that the 50% 
threshold was too high, and stated that a 25% reduction in AN count, provided there was no increase 
in abscesses or draining fistulas from baseline, would reflect a treatment response. Clinical experts 
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suggested that if the reduction in AN count was between 25% and 50%, they would continue with the 
existing treatment but may prescribe additional concomitant treatments (e.g. anti-inflammatories, 
retinoids and antibiotics) to improve response. The committee heard from experts that they would stop 
treatment if the reduction in AN count was lower than 25%, or if there was an increase in abscesses or 
draining fistulas. The clinical experts stated that it was important to also use PROMs when monitoring 
people with HS (in particular, the DLQI, the pain visual analogue scale [VAS] and the SF-36, even 
though they are not specific to this indication), because physician-reported and patient-reported scores 
do not always correlate. The committee concluded that it is appropriate to use HiSCR for assessing 
treatment response, with supporting information provided by PROMs.  
 
5.1.2 Clinical effectiveness of adalimumab for HS 
The committee discussed the clinical evidence for adalimumab and noted that people treated with 
adalimumab were more likely to have a clinical response than people treated with placebo and that 
this difference was significant. The committee was aware that the benefit with adalimumab was 
greater in PIONEER II than PIONEER I, possibly because PIONEER II patients appeared to have had 
less severe disease than those in PIONEER I, and had potentially received higher levels of systemic 
antibiotics. The company noted that only 19% of patients in PIONEER II took oral antibiotics during 
the trial. The committee noted that the company had not originally undertaken a formal meta-analysis 
and was concerned that they had given contradictory views on whether the PIONEER trials had 
similar or heterogeneous baseline characteristics, but concluded that the trials were generalisable to 
UK clinical practice. The committee was concerned that the OLE study only had data up to 72 weeks, 
given that adalimumab may be used for many years, and that full data were only available for 26% of 
enrolled patients. The committee concluded that adalimumab provided significant benefits compared 
with placebo, but these had not been shown over the long-term. The committee was also aware that 
adalimumab showed a beneficial effect on the SF-36 (collected in PIONEER I) and the DLQI 
(collected in PIONEER I and II) but noted that the difference between adalimumab and placebo was 
not significant for all components of the SF-36, and that the difference between arms in DLQI 
improvement at week 12 was not greater than the MCID. The committee considered that the DLQI 
PD\ KDYH XQGHUHVWLPDWHG WKH EHQHILFLDO HIIHFWV RI DGDOLPXPDE EDVHG RQ WKH FOLQLFDO H[SHUWV¶
comments that people with chronic skin conditions can develop coping mechanisms, which may result 
in lower DLQI scores than would be expected. The committee concluded that adalimumab had a 
statistically significant and clinically meaningful positive effect on HRQoL. 
 
5.1.3 Uncertainty surrounding the cost-effectiveness of adalimumab for HS 
The committee attempted to identify the most plausible ICER for adalimumab compared with 
supportive care. The committee considered that the resource XVH DVVXPSWLRQV LQ WKH (5*¶V QHZ 
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exploratory analyses, provided after consultation, were more realistic than the assumptions in the 
FRPSDQ\¶V UHYLVHG PRGHO 7KH FRPPLWWHH DOVR SUHIHUUHG WKH (5*¶V DVVXPSWLRQ WKDW WKHUH LV QR
lifelong difference in prognosis between people who previously had adalimumab and then stopped 
treatment, and those who had neYHUKDGWKHGUXJ,WDJUHHGZLWKWKH(5*¶VFRUUHFWHGGLVFRQWLQXDWLRQ
rate for weeks 12-36 %DVHG RQ WKH (5*¶V H[SORUDWRU\ DQDO\VHV WKH FRPPLWWHH FRQFOXGHG WKDW WKH
maximum possible probabilistic ICER for adalimumab compared with supportive care was between 
£28,500 and £33,200 per QALY gained. However, the committee considered that the most plausible 
,&(5ZRXOGEHORZHUWKDQWKLVIRUVHYHUDOUHDVRQV)LUVWWKH(5*¶VDVVXPSWLRQRIa maximum of 4 
ZLGHH[FLVLRQVRYHUDSDWLHQW¶VOLIHWLPHPD\EHDQXQGHUHVWLPDte, and the committee understood that 
the ICER reduced as the number of wide excisions increased. Second, the committee acknowledged 
that adalimumab may be associated with short-term improvements in psychological wellbeing after 
treatment is stopped, and sR FRQVLGHUHG WKDW WKH (5*¶V DVVXPSWLRQ DERXW SURJQRVLV ZDV SRVVLEO\
pessimistic and may have overestimated the ICER. The committee also considered that if its preferred 
definitions of partial response and non-UHVSRQVH KDG EHHQ LQFRUSRUDWHG LQ WKH (5*¶V H[Sloratory 
analyses, the ICER would have been reduced because continued treatment in people for whom a drug 
is not effective would be minimised.  
 
$335$,6$/&200,77((¶6.(<&21&/86,21 
The committee concluded that adalimumab provided significant benefits compared with placebo, but 
that these had not been shown over the long-term. The committee also concluded that the maximum 
possible ICER for adalimumab compared with supportive care was between £28,500 and £33,200 per 
QALY gained, but could be lower.  
 
ACKNOWLEDGEMENTS 
This project was funded by the National Institute for Health Research (NIHR) Health Technology 
Assessment Programme (project no. 15/06/09). See the HTA programme website for further project 
information (http://www.hta.ac.uk). This summary of the ERG report was compiled after NICE issued 
the FAD. All authors have commented on the submitted manuscript and have given their approval for 
the final version to be published. The views expressed in this report are those of the authors and not 
necessarily those of the NIHR HTA Programme. Any errors are the responsibility of the authors. 
 
COMPLIANCE WITH ETHICAL STANDARDS 
Conflicts of interest  
John lngram was a local principal investigator for an observational hidradenitis suppurativa study 
sponsored by AbbVie. Dr lngram has agreed to speak at a hidradenitis suppurativa innovation forum 
sponsored by AbbVie; he will receive travel expenses to attend but has donated his speakeU¶s 
18 
 
honorarium to charity. Fiona Collier provided some informal comments by email to AbbVie on their 
submission of adalimimab for treatment of hidradenitis suppurativa to the Scottish Medicines 
Consortium in 2015; this was unpaid. Dr Collier was a site co-investigator in an observational study 
of associations and disease course of hidradenitis suppurativa, funded by AbbVie in 2014; Dr Collier 
received no payment from AbbVie.  Dr Collier received payment by NHS Forth Valley for 4 extra 
clinic sessions to recruit and enrol patients in the study. NHS Forth Valley received payment from 
AbbVie patient recruited. Paul Tappenden, Christopher Carroll, John Stevens, Andrew Rawdin, 
Sabine Grimm, Mohammad Ghazavi and Eva Kaltenthaler declare no financial conflicts of interest. 
 
Contributions made by each author  
Christopher Carroll and Eva Kaltenthaler summarised and critiqued the clinical effectiveness data 
UHSRUWHG ZLWKLQ WKH FRPSDQ\¶V VXEPLVVLRQ Mark Clowes FULWLTXHG WKH FRPSDQ\¶V VHDUFK VWUDWHJ\
John Stevens critiqued the statistical analyses undertaken by the company. Sabine Grimm revised the 
FRPSDQ\¶V UHYLHZ RI H[LVWLQJ PRGHOV Paul Tappenden and Andrew Rawdin critiqued the health 
economic analysis submitted by the company and XQGHUWRRN WKH(5*¶V H[SORUDWRU\ DQDO\VHV John 
Ingram, Fiona Collier and Mohammad Ghazavi provided clinical advice to the ERG throughout the 
project. All authors were involved in drafting and commenting on the final report. Paul Tappenden 
acts as the guarantor of the manuscript. 
  
19 
 
REFERENCES 
1. National Institute for Health and Care Excellence. Guide to the processes of technology 
appraisal. London. 2014. 
2. Tappenden P, Carroll C, Stevens JW, Rawdin A, Grimm S, Clowes M. Adalimumab for treating 
moderate to severe hidradenitis suppurativa: A Single Technology Appraisal. Sheffield. 2015. 
3. Tappenden P, Carroll C, Stevens JW, Rawdin A, Grimm S, Clowes M. Adalimumab for treating 
moderate to severe hidradenitis suppurativa: A Single Technology Appraisal. Addendum: Patient 
Access Scheme. Sheffield. 2016. 
4. Tappenden P, Carroll C, Stevens JW, Rawdin A, Grimm S, Clowes M. Adalimumab for treating 
moderate to severe hidradenitis suppurativa: A Single Technology Appraisal. Addendum: ERG 
FULWLTXHRIFRPSDQ\¶V$&'UHVSRQVH6KHIILHOG. 2016. 
5. National Institute for Health and Care Excellence. Technology Appraisal Guidance: Adalimumab 
for treating moderate to severe hidradenitis suppurativa. London. 2016. 
6. Von Der Werth JM, Jemec GBE. Morbidity in patients with hidradenitis suppurativa. British 
Journal of Dermatology 2001;144(4):809±13. 
7. von der Werth JM, Williams HC. The natural history of hidradenitis suppurativa. Journal of the 
European Academy of Dermatology and Venereology 2000;14(5):389-92. 
8. Revuz J. Hidradenitis suppurativa. Journal of the European Academy of Dermatology and 
Venereology 2009;23:985-98. 
9. Jemec G. Clinical practice. Hidradenitis suppurativa. New England Journal of Medicine 
2012;366:158-64. 
10. Dufour D, Emtestam L, Jemec G. Hidradenitis suppurativa: a common and burdensome, yet 
under-recognised, inflammatory skin disease. Postgraduate Medical Journal 2014;90(1062):216-
21. 
11. Zouboulis C, Desai N, Emtestam L. European S1 guideline for the treatment of hidradenitis 
suppurativa/acne inversa. Journal of the European Academy of Dermatology and Venereology 
2015;29(4):619-44. 
12. Blok J, van Hattem S, Jonkman M, Horváth B. Systemic therapy with immunosuppressive agents 
and retinoids in hidradenitis suppurativa: a systematic review. British Journal of Dermatology 
2013;168(2):243-52. 
13. Ingram J, McPhee M. Management of hidradenitis suppurativa: a UK survey of current practice. 
British Journal of Dermatology 2015;173(4):1070-2. 
14. National Institute for Health and Care Excellence. Adalimumab for treating moderate to severe 
hidradenitis suppurativa - Final scope. London. 2015. 
15. AbbVie Ltd. Adalimumab for treating moderate to severe hidradenitis suppurativa. ID812. 
Company evidence submission to the National Institute for Health and Care Excellence. . 
Berkshire. 2015. 
16. AbbVie Ltd. Adalimumab for treating moderate to severe hidradenitis suppurativa. ID812. 
Response to ERG's clarification questions. Berkshire. 2015. 
17. Kimball A, Jemec GB, Yang M, Kageleiry A, Signorovitch JE, Okun MM, et al. Assessing the 
validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response 
(HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. British Journal of 
Dermatology 2014;171(6):1434-42. 
20 
 
18. AbbVie Ltd. A Phase 3 multicenter study of the safety and efficacy of adalimumab in subjects 
with moderate to severe hidradenitis suppurativa  ± PIONEER I. Clinical Study Report (Interim), 
Adalimumab/Protocol. 2015. 
19. AbbVie Ltd. A Phase 3 multicenter study of the safety and efficacy of adalimumab in subjects 
with moderate to severe hidradenitis suppurativa  ± PIONEER II (Clinical Study Report 
(Interim), Adalimumab/Protocol M11-810). 2015. 
20. AbbVie Ltd. Phase 3 open-label study of the safety and  efficacy of adalimumab in subjects with 
moderate to severe hidradenitis suppurativa  ± PIONEER (open-label extension) Clinical Study 
Report (Interim), Adalimumab/Protocol M12-555. 2015. 
21. Ingram JR. Hidradenitis suppurativa outcome measures and treatment goals. British Journal of 
Dermatology 2014:171(6);1293-4. 
22. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 
[updated March 2011]. 2011. 
23. Critical Appraisal Skills Programme (CASP). Cohort Study Checklist. 2013. 
24. BMJ Group, RCPCH Publications Ltd and The Royal Pharmaceutical Society of Great Britain. 
British National Formulary (BNF). 2015. 
25. Curtis L. Costs of health and social care 2014. University of Kent, UK. 2014. 
26. Department of Health. NHS Reference Costs 2013/14. 2014. 
27. National Institute for Health and Care Excellence. Final appraisal determination: Adalimumab 
for treating moderate to severe hidradenitis suppurativa. London. 2016. 
 
 
  
21 
 
Table 1: HiSCR response categories 
HiSCR-based state 
definition 
HiSCR-based state description 
High response At least 75% total AN count reduction, with no increase in abscesses or 
draining fistulas from baseline 
Response At least 50% but less than 75% AN reduction, with no increase in abscesses 
or draining fistulas from baseline 
Partial response At least 25% but less than 50% AN reduction, with no increase in abscesses 
or draining fistulas from baseline; or at least 25% AN reductions, with an 
increase in abscesses and/or draining fistulas 
No response Defined as less than 25% AN reduction 
HiSCR - Hidradenitis Suppurativa Clinical Response; AN - abscess and inflammatory nodule  
 
Table 2: Evidence used to inform the model transition matrices 
Matrix description Source 
Standard care ± induction phase 
Week 0-12 Cross-tabs of outcomes based on pooling of patients initially 
randomised to the placebo groups within PIONEER I/II 
Standard care ± maintenance phase 
Week 12-36 Cross-tabs of outcomes for patients initially randomised to the 
placebo group in PIONEER II who subsequently continued on 
placebo during maintenance. 
Week 36+ GLM based on 12-36 week data described above 
Adalimumab ± induction phase 
Week 0-12 Cross-tabs of outcomes based on pooling of patients initially 
randomised to adalimumab 40mg EW groups within PIONEER 
I/II. 
Maintenance phase ± adalimumab 12-week responders 
Week 12-36 Cross-tabs of adalimumab 40mg EW patients re-randomised to 
adalimumab 40mg EW after responding at 12-weeks in 
PIONEER I/II. 
Week 36-48 GLM based on weeks 0-24 of M12-555 OLE study (including 
LOCF imputation as <50% patients had 24-weeks follow-up 
data). 
Week 48+ Same as above except the probability of transiting from 
adalimumab no response state to standard care no response state 
is cubed. 
Maintenance phase ± adalimumab 12-week non-responders and subsequent discontinuers 
Week 12-36 Cross-tabs of patients randomised to adalimumab 40mg EW in 
PIONEER I/II who switched to placebo in the maintenance 
period (irrespective of whether they achieved an induction 
response on adalimumab). 
Week 36+ GLM based on week 12-36 data described above 
GLM ± generalised linear model; OLE ± open-label extension; LOCF ± last observation carried forward; mg ± milligram; 
EW ± every week 
 
 
